Literature DB >> 18843001

Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.

Julia S Johansen1, Tine Lottenburger, Hans Jørgen Nielsen, Jens Erik B Jensen, Mads N Svendsen, Gine Kollerup, Ib J Christensen.   

Abstract

Serum YKL-40 is a potential biomarker of prognosis in cancer patients, but assessment of serum YKL-40 requires knowledge of its normal variation. In this study, we evaluated diurnal, weekly, and long-term variation in serum YKL-40 in healthy subjects using a commercial ELISA. The intra-assay coefficient of variation was <or=5.0% and interassay <or=10.2%. Systematic changes in diurnal measurements of serum YKL-40 could not be shown. Physical exercise for 20 min had no effect on serum YKL-40. The within-subject coefficient of variation, including variation over time and interassay, was 28.8% and 30.2% over a period of 2 and 3 years, and the intraclass correlation coefficients were 72.4% and 72.2%, indicating reasonable reliability of serum YKL-40 measurements. The 95% confidence limits for the difference between two measurements (same subject), including interassay variation, were a 52% reduction and a 109% increase in serum YKL-40. These studies show that relatively small variation is found in serum YKL-40 in healthy subjects. However, a single measurement of serum YKL-40 from an individual may not have a prognostic value, and serum YKL-40 alone cannot be a good biomarker for cancer because serum YKL-40 can be elevated in patients with other diseases characterized by inflammation and tissue remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843001     DOI: 10.1158/1055-9965.EPI-07-2766

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  24 in total

1.  The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.

Authors:  Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup
Journal:  Inflamm Res       Date:  2010-10-23       Impact factor: 4.575

2.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Authors:  Fabio M Iwamoto; Andreas F Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Lisa M DeAngelis; Eric C Holland; Adília Hormigo
Journal:  Neuro Oncol       Date:  2011-08-10       Impact factor: 12.300

3.  The impact of acute aerobic exercise on chitinase 3-like protein 1 and intelectin-1 expression in obesity.

Authors:  Chun-Jung Huang; Aaron L Slusher; Michael Whitehurst; Marie Wells; Arun Maharaj; Yoshimi Shibata
Journal:  Exp Biol Med (Maywood)       Date:  2015-08-27

4.  YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome.

Authors:  Tansu Gonen; Savas Guzel; Kadircan H Keskinbora
Journal:  Eye (Lond)       Date:  2018-12-18       Impact factor: 3.775

5.  C-reactive protein and chitinase 3-like protein 1 as biomarkers of spatial redistribution of retinal blood vessels on digital retinal photography in patients with diabetic retinopathy.

Authors:  Sonja Cekić; Tatjana Cvetković; Ivan Jovanović; Predrag Jovanović; Milica Pesić; Gordana Stanković Babić; Svetislav Milenković; Dijana Risimić
Journal:  Bosn J Basic Med Sci       Date:  2014-08-20       Impact factor: 3.363

6.  Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?

Authors:  Gamze Erfan; Savas Guzel; Seref Alpsoy; Emine N Rifaioglu; Sule Kaya; Volkan Kucukyalcın; Birol Topcu; Mustafa Kulac
Journal:  Mol Cell Biochem       Date:  2014-11-25       Impact factor: 3.396

Review 7.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

8.  Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease.

Authors:  Xue Xu; Hongling Ma; Jia Xu; Haiwei Huang; Xiaohong Wu; Yan Xiong; Hong Zhan; Fan Huang
Journal:  Bosn J Basic Med Sci       Date:  2014-08-14       Impact factor: 3.363

9.  The relation of circulating YKL-40 to levels and decline of lung function in adult life.

Authors:  Stefano Guerra; Marilyn Halonen; Duane L Sherrill; Claire Venker; Amber Spangenberg; Anne-elie Carsin; Lluïsa Tarès; Iris Lavi; Esther Barreiro; Jesús Martínez-Moratalla; Isabel Urrutia; Jordi Sunyer; Josep M Antó; Fernando D Martinez
Journal:  Respir Med       Date:  2013-08-03       Impact factor: 3.415

Review 10.  YKL-40--an emerging biomarker in cardiovascular disease and diabetes.

Authors:  Camilla N Rathcke; Henrik Vestergaard
Journal:  Cardiovasc Diabetol       Date:  2009-11-23       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.